DE:6Y4 Stock Latest News
Company AnnouncementsVicore’s IPF Drug Clears Futility Test as ASPIRE Trial Marches Toward 2027 Readout1w ago
Company AnnouncementsVicore Pharma to Spotlight IPF Program at Chardan Healthcare Conference2w ago
The FlyVicore Pharma initiated with a Buy at Jefferies3w agoVCRE
Company AnnouncementsVicore Pharma boosts share capital as board incentives convert to equity1M ago
Company AnnouncementsVicore Pharma to Spotlight IPF Program at Stifel Immunology Forum1M ago
Company AnnouncementsVicore Pharma to Highlight IPF Program at Major U.S. Healthcare Conferences2M agoCompany AnnouncementsVicore Pharma to Highlight ATRAG Pipeline at Pareto Healthcare Conference2M ago
Company AnnouncementsVicore Pharma Showcases Buloxibutid IPF Data at ERS 2026 as Phase 2b Trial Advances2M ago
Company AnnouncementsVicore Pharma Issues Comprehensive Q2 2026 Interim Report2M ago
Pre-Earnings6Y4 Earnings this Week: How Will it Perform?2M ago
Company AnnouncementsVicore Pharma to Join Leerink Therapeutics Forum Amid Progress in IPF Program3M ago- Company AnnouncementsVicore Pharma Bolsters R&D Leadership With New Chief Scientific Officer3M ago
Company AnnouncementsVicore Pharma Begins Trading ADSs on Nasdaq U.S. in Dual-Listing Move4M ago
Company AnnouncementsVicore Pharma to Spotlight IPF Program at Jefferies Global Healthcare Conference5M ago
- Company AnnouncementsVicore Pharma Seeks US Dual Listing as Lead IPF Drug Nears Key Readout5M ago
Company AnnouncementsVicore Pharma Adds Veteran Pharma Executive Peter Guenter to Board Ahead of Key IPF Milestone5M ago- Company AnnouncementsVicore Pharma AGM Backs Expanded Capital Authority and New RSU Plan for Board5M ago
Company AnnouncementsVicore Pharma Publishes Q1 2026 Interim Report5M ago
Company AnnouncementsVicore Pharma to Spotlight Buloxibutid Data at 2026 ATS Meeting6M ago